An evaluation of empagliflozin and it’s applicability to hypertension as a therapeutic option

Clicks: 342
ID: 111714
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #6 of 7 articles by views in expert opinion on pharmacotherapy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract is not available for this article.
Login to Search Abstract
Reference Key
schlaich2020expertan Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lakshini Y Herat,Vance B Matthews,Aaron L Magno,Marcio G Kiuchi,Revathy Carnagarin,Markus Schlaich;Lakshini Y Herat;Vance B Matthews;Aaron L Magno;Marcio G Kiuchi;Revathy Carnagarin;Markus Schlaich;
Journal expert opinion on pharmacotherapy
Year 2020
DOI
10.1080/14656566.2020.1751815
URL
https://sciprofiles.com/publication/view/af977d36d6bdebe7d9b36ed786b95eef
Keywords
hypertension Diabetes cardiovascular disease empagliflozin sglt2 sglt2 inhibitors

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.